StockData
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc. (LXRX) stock

LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)

Close on Nov 17, 2026Market cap $792.02MP/E –Yield –

Lexicon Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Lexicon Pharmaceuticals's total debt was $51.44M at Jun 30, 2026. For fiscal 2025 it was $54.00M, down 46.2% from the year before. Over ten years it grew -6.2% a year on average. The highest annual figure on record is $245.67M in fiscal 2017.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$54.00M-46.2%
FY2024Dec 31, 2024$100.30M+0.8%
FY2023Dec 31, 2023$99.51M+104.8%
FY2022Dec 31, 2022$48.58M–
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$11.65M-95.3%
FY2019Dec 31, 2019$245.18M+0.1%
FY2018Dec 31, 2018$245.00M-0.3%
FY2017Dec 31, 2017$245.67M+142.2%
FY2016Dec 31, 2016$101.45M-1.4%
FY2015Dec 31, 2015$102.94M-4.4%
FY2014Dec 31, 2014$107.67M+392.1%
FY2013Dec 31, 2013$21.88M-6.7%
FY2012Dec 31, 2012$23.45M-5.8%
FY2011Dec 31, 2011$24.89M-12.6%
FY2010Dec 31, 2010$28.48M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$51.44M-8.3%
Q1 FY2026Mar 31, 2026$49.68M-50.7%
Q4 FY2025Dec 31, 2025$54.00M-46.2%
Q3 FY2025Sep 30, 2025$56.51M-43.4%
Q2 FY2025Jun 30, 2025$56.11M-43.6%
Q1 FY2025Mar 31, 2025$100.70M+0.8%
Q4 FY2024Dec 31, 2024$100.30M+0.8%
Q3 FY2024Sep 30, 2024$99.90M+0.6%
Q2 FY2024Jun 30, 2024$99.50M+0.7%
Q1 FY2024Mar 31, 2024$99.87M+104.5%
Q4 FY2023Dec 31, 2023$99.51M+104.8%
Q3 FY2023Sep 30, 2023$99.27M+317.4%
Q2 FY2023Jun 30, 2023$98.77M+318.0%
Q1 FY2023Mar 31, 2023$48.85M+108.1%
Q4 FY2022Dec 31, 2022$48.58M–
Q3 FY2022Sep 30, 2022$23.78M+80.5%
Q2 FY2022Jun 30, 2022$23.63M+77.7%
Q1 FY2022Mar 31, 2022$23.48M+75.5%
Q4 FY2021Dec 31, 2021$0-100.0%
Q3 FY2021Sep 30, 2021$13.17M-35.2%
Q2 FY2021Jun 30, 2021$13.30M-94.6%
Q1 FY2021Mar 31, 2021$13.38M-94.5%
Q4 FY2020Dec 31, 2020$11.65M-95.3%
Q3 FY2020Sep 30, 2020$20.32M-91.7%
Q2 FY2020Jun 30, 2020$245.26M+0.1%
Q1 FY2020Mar 31, 2020$245.22M+0.1%
Q4 FY2019Dec 31, 2019$245.18M+0.1%
Q3 FY2019Sep 30, 2019$245.13M+0.1%
Q2 FY2019Jun 30, 2019$245.07M-0.0%
Q1 FY2019Mar 31, 2019$245.03M-0.2%
Q4 FY2018Dec 31, 2018$245.00M-0.3%
Q3 FY2018Sep 30, 2018$244.95M+144.6%
Q2 FY2018Jun 30, 2018$245.09M+143.8%
Q1 FY2018Mar 31, 2018$245.40M+142.9%
Q4 FY2017Dec 31, 2017$245.67M+142.2%
Q3 FY2017Sep 30, 2017$100.15M-1.7%
Q2 FY2017Jun 30, 2017$100.54M–
Q1 FY2017Mar 31, 2017$101.02M–
Q4 FY2016Dec 31, 2016$101.45M–
Q3 FY2016Sep 30, 2016$101.83M–

More Lexicon Pharmaceuticals figures

See a number that looks wrong?